Details
Category: Achievements
Hits: 61

Prof. dr hab. med. Anna Członkowska, II Klinika Neurologii, Instytut Psychiatrii i Neurologii, Warszawa

The article presents a summary of the results from five analyses, focusing on impact of COVID-19 on stroke care including: ischaemic stroke, reperfusion therapy, subarachnoid haemorrhage, and cerebral venous thrombosis, before and during the pandemic (COVID-19), analyzing the contribution of Polish centres.
Paper: International Study: Global Impact of COVID 19 on Stroke Care – Polish participation. Lasek-Bal A, Członkowska A, Qureshi MM, Abdalkader M, Marto JM, Michel P, Yamagami H, Mikulik R, Demeestere J, Qiu Z, Nguyen TN, Nogueira RG, Neurol Neurochir PoI, accepted to press 27.01.2023.

The analysis of the clinical characteristics Wilson’s disease patients admitted, diagnosed and treated in Institute Psychiatry and Neurology, Warsaw, Poland over seven decades (pre-1959 to 2019).
Paper: Seven decades of clinical experience with Wilson’s disease: report from the national reference center in Poland. Członkowska A, Niewada M, Litwin T, Kraiński Ł, Skowrońska M, Piechal A, Antos A, Misztal M, Khanna I, Kurkowska-Jastrzębska I. Eur J Neurol, 2022, doi: 10.1111/ene.15646

 

Prof. dr hab. med. Dariusz J. Jaskólski, Klinika Neurochirurgii i Onkologii Układu Nerwowego UM w Łodzi

It has been established that the level of hydroxyproline and phenylanaline in the plasma of patients operated on for ruptured intracranial aneurysm is an important prognostic factor for the occurrence of cerebral vasospasm (CVS) - a serious complication of subarachnoid hemorrhage - so taking them into account greatly improves the sensitivity and specificity of the Hunt and Hess scale in predicting the occurrence of this complication.
Paper: Plasma Amino Acids May Improve Prediction Accuracy of Cerebral Vasospasm after Aneurysmal Subarachnoid Haemorrhage, Bobeff EJ, Bukowiecka-Matusiak M, Stawiski K, Wiśniewski K, Burzyńska-Pędziwiatr I, Kordzińska M, Kowalski K, Sendys P, Piotrowski M, Szczęsna D, Stefańczyk L, Woźniak LA, Jaskólski DJ. J Clin Med. 2022 Jan 13;11(2):380. doi: 10.3390/jcm11020380.

 

Dr hab. n. med Tomasz Litwin, prof. IPiN, Instytut Psychiatrii i Neurologii, II Klinika Neurologii, Warszawa

First ever longitudinal prospective study with objective Viena software which analyzed at diagnosis and in 2 years follow-up brain atrophy in Wilson’s disease(WD) patients. The study documented that brain atrophy could be a very sensitive biomarker of neurological involvement in WD, especially in patients who neurologically deteriorated.
Paper: Brain Atrophy Is Substantially Accelerated in Neurological Wilson’s Disease: A Longitudinal Study. Smoliński Ł, Ziemssen T, Akgun K, Antos A, Skowrońska M, Kurkowska-Jastrzębska I., Członkowska A, Litwin T. Mov Disord 2022; 37: 2446-245

The neuroradiological analysis of 100 Wilson’s disease patients (newly diagnosed) according to brain MRI and potentially pathognomonic neuroradiological symptoms (frequency and significance).
Paper: Pathognomonic Neuroradiological Signs in Wilson’s Disease - Truth or Myth? Rędzia-Ogrodnik B, Członkowska A, Antos A, Bembenek J, Kurkowska-Jastrzębska I, Przybyłkowski A, Skowrońska M, Smoliński Ł, Litwin T. Park Rel Disord 2022, DOI: 10.1016/j.parkreldis.2022.105247, 1-17

 

Prof. dr hab. n. med. Barbara Mroczko, Zakład Diagnostyki Chorób Neurozwyrodnieniowych, Uniwersytet Medyczny w Białymstoku

This finding suggests that preclinical and prodromal Alzheimer's disease may be more prevalent than previously estimated, with important implications for clinical trial recruitment strategies and healthcare planning policies. The study showed that an estimate of the prevalence of amyloid abnormalities based on cerebrospinal fluid results using appropriately adjusted cut-off values (i.e. adjusted cut-off points) to the available data was up to 10% higher than the predicted presence of amyloid pathology assessed by PET scan in people without dementia, similar results were obtained in people with dementia.
Paper: Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. Jansen WJ, Janssen O, Tijms BM, (…) Mroczko B. (…), Yen Tzu-C, Zboch M, Zetterberg H. JAMA Neurology 2022, 79, 3, 228-243

Evaluation of the clinical utility of biomarkers of neurodegeneration and axonal dysfunction in patients with multiple sclerosis (MS). The study showed that all of the proteins tested in the cerebrospinal fluid, i.e. NFL (neurofilaments light chain), RTN-4 (reticulon-4), Tau, allowed the differentiation of MS from controls (including neurological patients with non-inflammatory diseases CNS). However, a significant correlation with demyelinating lesions assessed by magnetic resonance imaging and the highest diagnostic value, were observed in the case of NFL.
Paper: Comparative Analysis of Neurodegeneration and Axonal Dysfunction Biomarkers in the Cerebrospinal Fluid of Patients with Multiple Sclerosis. Kulczyńska-Przybik A, Dulewicz M, Doroszkiewicz J, Borawska R, Litman-Zawadzka A, Arslan D, Kułakowska A, Kochanowicz J, Mroczko B. J Clin Med, 2022 Jul 15;11(14):4122. doi: 10.3390/jcm11144122.

The use of bioinformatic analysis and studies of biomarkers in the cerebrospinal fluid in the assessment of synaptic disorders in mild cognitive impairment and Alzheimer's disease. Both the functional analysis of the tested proteins and the quantitative assessment confirmed that neurogranin (Ng) and neuronal pentraxin receptor (NPTXR) may be promising biomarkers of synaptic dysfunction in the early diagnosis of cognitive disorders. Both proteins seem to be functionally related during some biological processes taking place at the basic physiological level. Their important role also in pathological conditions is confirmed by the calculated NPTXR/Ng ratio, which shows a significant diagnostic value already at the stage of mild cognitive disorders. Mapping the common molecular and biological functions of the tested proteins with use of gene ontology (GO) enrichment analysis can be beneficial in screening as well as in setting new therapeutic targets.
Paper: Evaluation of synaptic and axonal dysfunction biomarkers in Alzheimer's disease and mild cognitive impairment based on CSF and bioinformatic analysis. Dulewicz M, Kulczyńska-Przybik A, Borawska R, Słowik A, Mroczko B. International Journal of Molecular Sciences 2022, 23, 18, 11, Article ID 10867

 

Prof. dr hab. Edyta Szurowska, Il Zakład Radiologii, Gdański Uniwersytet Medyczny

Previous neuroscientific studies on the brain-gut axis indicate the presence of a bidirectional system that may induce different dysfunction in patients with inflammatory and functional bowel diseases. The volumetry was used to assess the microstructural changes of subcortical structures in patients with non-specific digestive disorders (functional dyspepsia - FD, irritable bowel syndrome - IBS) and non-specific inflammatory bowel diseases—IBD (colitis ulcerosa and Crohn’s disease), in comparison to the healthy control group. The thalamus, responsible for integrating sensory and motor information transmitted to the cortex, was smaller in IBD patients in comparison to both the IBS and control group.
Paper: Evaluation of Subcortical Structure Volumes in Patients with Non-Specific Digestive Diseases. Skrobisz K, Piotrowicz G, Rudnik A, Naumczyk P, Sabisz A, Markiet K, Szurowska E. Diagnostics (Basel). 2022; 12(9): 2199 doi: 10.3390/diagnostics12092199.

The hypothesis of the research was to find out if Peak width Skeletonized Mean Diffusivity (PSMD) may be a predictive factor in relapsing-remitting multiple sclerosis (RRMS). According to our study, PSMD is a new white matter (WM) microstructure damage marker that is a contributor to complex cognitive tasks, California Verbal Learning Test (CVLT) performance, and semantic fluency, as well as upper extremity disability together with WM hypointensities and normalized brain volume (NBV).
Paper: Skeletonized mean diffusivity and neuropsychological performance in relapsing-remitting multiple sclerosis .Chylińska M, Karaszewski B, Komendzióski J, Wyszomirski A, Sabisz A, Halas M, Szurowska E. Brain Behav, 2022 Jun;12(6):e2591. doi: 10.1002/brb3.2591.

The paper provides a state-of-the-art review with regard to tuberous sclerosis complex -neuropsychiatric disorders (TSC‐associated neuropsychiatric disorders, TAND) and describes diagnostic criteria, neuroanatomical pathology and pathophysiology of psychiatric, neuropsychological, developmental and psychosocial symptoms present in TSC, as well as differences between patients with or without epilepsy and/or intellectual disability. The importance of a proper diagnosis of neuropsychiatric disorders and multidisciplinary patient care was emphasized.
Paper: Tuberous sclerosis complex-associated neuropsychiatric disorders. Marcinkowska AB, Tarasewicz A, Jóżwiak S, Debska-Ślizień A, Szurowska E. Psychiatr Pol, 2022 May 3:1-20. English, Polish. doi: 10.12740/PP/OnlineFirst/146265.

The main complication of an intravenous administration of recombinant tissue plasminogen activator (rtPA) in patients with acute ischemic stroke (AIS) is symptomatic intracranial hemorrhage, but rtPA use might also be connected with cerebral microbleeds (CMBs) formation. According to our study, baseline CMBs correlated with a higher risk of new CMBs appearing after the rtPA treatment, independently of other factors, but did not correlate with an increased risk of a hemorrhagic transformation of ischemic stroke.
Paper: New Remote Cerebral Microbleeds on TX-Weighted Echo Planar MRI After Intravenous Thrombolysis for Acute Ischemic Stroke. Jabłoński B, Gójska-Grymajko A, Ossowska D, Szurowska E, Wyszomirski A, Rojek B, Karaszewski B. Front Neurol, 2022 Feb 15;12:744701. doi: 10.3389/fneur.2021.744701.

The study assesses the diagnostic value of diffusion tensor imaging (DTI) in patients with symptoms of cervical myelopathy. Changes in DTI parameters indicate a microstructural disorder of the spinal cord which is not visible in a structural MRI, and allow the differentiation of patients with myelopathy as well as potentially being helpful in treatment planning (conservative vs. surgical) for patients with visible canal stenosis.
Paper: Diagnostic value of diffusion tensor imaging in patients with clinical signs of cervical spondylotic myelopathy.Skotarczak M, Dzierżanowski J, Kaszubowski M, Winklewski PJ, Romanowski A, Szurowska E, Szarmach A. Neurol Neurochir PoI, 2022;56(4):341-348. doi: 10.5603/PJNNS.a2022.0031.

 

Dr hab. n. med. Anna SARNOWSKA, prof. IMDiK, Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

Current knowledge shows that even small changes in the cell environment may result in obtaining a subpopulation of cells with different therapeutic properties. For this reason, the conditions of mesenchymal stem/stromal cell transportation, isolation, cultivation and banking destined for clinical use should be unified and optimized. Based on the obtained results, a protocol for manufacturing an advanced-therapy medicinal product was composed.
Paper: Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton's Jelly. Sypecka M, Bzinkowska A, Sulejczak D, Dabrowski F, Sarnowska A. Int J Mol Sci, 2022 Dec 30;24(1):652. doi: 10.3390/ijms24010652. PMID: 36614096; PMCID: PMC9820979.

The interaction between stem cells and companion/supporting cells is crucial for homeostasis and tissue regeneration. It seems that mesenchyme as a component of the cell niche may play a role in the homeostasis between the population of quiescent SCs and the population of progenitors that proliferate, differentiate, and migrate from cell niche. The same interactions are described between NSCs and MSCs. As NSCs are potentially an unlimited source of all neural cell types and MSCs display a high paracrine activity, their combined therapeutic use for neurological disorders seems to be highly prospective.
Paper: Interaction of Neural Stem Cells (NSCs) and Mesenchymal Stem Cells (MSCs) as a Promising Approach in Brain Study and Nerve Regeneration. Kaminska A, Radoszkiewicz K, Rybkowska P, Wedzinska A, Sarnowska A. Cells 2022 Apr 26;11(9):1464. doi: 10.3390/cells11091464. PMID: 35563770; PMCID: PMC9105617.

To select the optimal and minimally invasive methods of adipose derived stem/stromal cells (ASC) transplantation, direct cell application with an irrigator or with skin dressings was analyzed. Our results confirmed that both the presented methods of cell application allow for the safe delivery of isolated ASC into wounds without losing their vitality. Cells propagated in the described conditions and applied in non‐invasive cell application (with an irrigation system and dressings) to treat chronic wounds can be a potential alternative or supplement to more invasive clinical approaches.
Paper: Efficiency assessment of irrigation as an alternative method for improving the regenerative potential of non-healing wounds. Figiel-Dabrowska A, Krzesniak NE, Noszczyk BH, Domanska-Janik K, Sarnowska A. Wound Repair Regen, 2022 May;30(3):303-316. doi: 10.1111/wrr.13013. PMID: 35384136; PMCID: PMC9321893.

Nowadays it is observed that the number of stem-cell based experimental therapies in neurodegenerative disorders is massively increasing. In the conducted clinical trials neither serious side effects, nor statistically significant improvement were observed. In the presented papers, we summarize, in our opinion, the most important factors that could increase the effectiveness of stem cell - based therapy.
Paper: Critical factors responsible for the therapeutic effect of mesenchymal stem/stromal cells in central nervous system disorders. Figiel-Dąbrowska A, Sypecka M, Chodkowska M, Sarnowska A. Folia Neuropathol, 2022;60(1):1-9. doi: 10.5114/fn.2022.114335. PMID: 35359141.

In this paper we provide the information on the application of cell therapy in orthopedics, hematology, ophthalmology, dermatology, gastrology and neurology. Advantages and disadvantages of application of different cell types for cell therapy are underlined. Last, but not least current law regulations in Poland and requirements of European regulatory bodies for cell therapy are pointed out and discussed.
Paper: Fakty i kontrowersje związane z terapią komórkową w medycynie regeneracyjnej. Sarnowska A, Machaliński B, Radoszkiewicz K, Bużańska L, NAUKA 4/2021 • 67–92 DOI: 10.24425/nauka.2021.137643

The manuscript describes the latest (published in 2021) discoveries regarding the pathogenesis of neurological diseases, neuroreconstructive mechanisms and clinical therapeutic achievements.
Paper: The 2021 yearbook of Neurorestoratology. Sharma H, Chopp M, Chen L, Sarnowska A, Xue M, Ao Q, Siniscalco D, Chen L, Hawamdeh Z, Huang H.Journal of Neurorestoratology, Volume 10, Issue 3, September 2022, doi.org/10.1016/j.jnrt.2022.100008

The International Association of Neurorestoratology (IANR) and the Chinese Association of Neurorestoratology (CANR; Preparatory) collaborated to release Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017) in 2018. Due to recent advances and achievements in clinical cell therapy worldwide in recent years, IANR and CANR have renewed and updated the guidelines. Except for the requirements of equipment, personnel, and ethics, these revised guidelines include cell type nomenclature, cell quality control, cell types in clinical application, minimal suggested cellular doses, patient-informed consent, indications and contraindications for undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, the policy of repeated treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility. IANR/CANR recommends that all clinical practitioners follow these cellular therapy guidelines.
Paper: Clinical cell therapy guidelines for neurorestoration (IANR/CANR 2022). Huang H, Al Zoubi Z, Moviglia G, Sharma HS, Sarnowska A, Sanberg PR, Chen L, Xue Q, Siniscalco D, Feng S, Saberi H, Guo X, Xue M, Dimitrijevic MR, Andrews RJ, Mao G, Chunhua Zhao R, Han F. Journal of Neurorestoratology, Volume 10, Issue 3,2022,100015,doi.org/10.1016/j.jnrt.2022.10001

 

 

 

Details
Category: Achievements
Hits: 96

Authors: prof. dr hab. n. med. Monika Adamczyk-Sowa, prof. dr hab. med. Anna Członkowska, prof. dr hab. n. med. Dariusz Jaskólski, dr hab. n. med. Adam Kobayashi, prof. nadzw., prof. dr hab. n. med. Tomasz Litwin, prof. dr hab. n. med. Barbara Mroczko, dr. hab. n. med. Joannna Siuda


Edited by prof. dr hab. n. med. Urszula Fiszer

 

Assessment of the clinical significance of biomarkers useful in the early diagnosis of neurodegenerative diseases (elaborated by Prof. dr hab.n. med. Barbara Mroczko: e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.)

Global: Due to the nonhomogeneous interpretation rates of Alzheimer's disease biomarker concentration results, a team of experts from the world's leading diagnostic centers standardized the comments corresponding to the different cerebrospinal fluid biomarker profiles. The most relevant and clinically useful comments on the interpretation of cerebrospinal fluid biomarkers of the disease were identified and selected.
Delaby C, Teunissen CE,…, Kulczynska-Przybik A, Lewczuk P, …, Mroczko B, …, Lehmann S. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer’s & Dement. 2021 Dec 22. doi: 10.1002/alz.12545. Online ahead of print. (IF-21.566, 200 pkt.)

Own: The presence of the protein reticulon 4 (RTN4) in cerebrospinal fluid was examined and compared in patients with various neurodegenerative diseases. In addition, we analyzed the potential use of this protein, as well as neurogranin (Ng) and neuronal pentraxin receptor (NPTXR), in clinical practice. Research results show that Ng and NPTXR, but especially the NPTXR/Ng ratio, are promising biomarkers of synaptic dysfunction reflecting early neuropathological changes in Alzheimer's disease. They also show that there is a relationship between RTN4 and key pathogenetic processes in the development of the studied diseases, including amyloidopathy, α-synucleinopathy and neurodegeneration.
Kulczyńska-Przybik A, Dulewicz M, Słowik A, Borawska R, Kułakowska A, Kochanowicz J, Mroczko B. J Clin Med. 2021:13;10(22):5281. (IF-4.242, 140 pkt.)
Dulewicz M, Kulczyńska-Przybik A, Słowik A, Borawska R, Mroczko B. Neurogranin and Neuronal Pentraxin Receptor as Synaptic Dysfunction Biomarkers in Alzheimer's Disease. J. Clin. Med. 2021;10(19):4575. (IF-4.242, 140 pkt.)

 

Assessment of the plasma biomakers specific for Alzheimer's Disease. (elaborated by dr hab. n. med. Joanna Siuda: e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.)

Global:The quantifiaction of phosphorylated at threonine tau proteine plasma level (p-tau 181, p-tau217 and p-tau231) is promising in detecting Alzheimer's disease (AD). The high plasma concentrations of these p-tau proteins is highly specific for neurodegeneration invovled in AD, and let us differentiate AD and non-AD neurodegenerative disorders (e.g. fronto-temporal dementia or dementia asscoiated with atypical parkinsonian syndromes). It also could suggest the high risk of AD development in presymptomatic patients or in mild cognitivie impairment (MCI) groups. In the near future, seems to be possible that’s the assesment of these biomarkers will be possible in the office of general practitioners, what improve the screening for AD in general population.
Ashton NJ, Pascoal T.A, Karikari T.K. i wsp. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology” Acta Neuropathologica 2021;141:709–724; https://doi.org/10.1007/s00401-021-02275-6
Cullen N.C, Leuzy A, Janelidze S. i wsp. Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nature Communications 2021;12:3555; https://doi.org/10.1038/s41467-021-23746-0
Thijssen E.H, La Joie R, Strom A. i wsp. Association of plasma P-tau217 and P-tau181 with clinical phenotype, neuropathology, and imaging markers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology 2021;20(9):739–752; https://doi.org/10.1016/S1474-4422(21)00214-3

 

The clinical significance of new biomarkers in Wilson’s disease diagnosis ( elaborated by dr hab. n. med. Tomasz Litwin, prof. IPiN; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.)

Global:In 2020 Shribman, et al. as the first discovered, that’s serum neurofilaments ligght chains (sNfL) concentrations in Wilson’s disease (WD) patients with involvement of central nervous system is elevated compared to healthy control or WD patients with only hepatic presentation. Further, WD patients with active neurological disease (progres of symptoms) had higher sNfL concentarions compared to stable patients. The authors suggested to include this biomarker to further studies in WD with new drugs as well as studies involving the course and prognosis of WD
Shribman S, Heller C, Burrows M, i wsp. Plasma neurofilament light as biomarker of neurological involvement in Wilson’s disease. Mov. Disord. 2020; 36: 503–508

Own:Looking for the biomarkers of brain injury in WD, based on the Shribamn, et al. paper together with Center of Clinical Neuroscience, Department of Neurology, University Clinic Carl Gustav Carus & Dresden University of Technology, Dresden, Germany we performed the analysis of sNfL in WD patients. In our results we found that’s the Neurofilament light chain may be used as a biomarker of brain injury in Wilson’s disease in addition to the clinical (UWDRS) and neuroimaging (semiquantitative brain MRI scale) disease severity scales.
Ziemssen T, Akgun K, Członkowska A, i wsp. Serum neurofilament light chain as a biomarker of brain injury in Wilson’s disease. Mov. Disord. 2022; DOI: 10.1002/mds.28946.
Dusek P, Smolinski L, Redzia-Ogrodnik B, i wsp. Semiquantitative scale for assessing brain MRI abnormalities in Wilson disease: a validation study, Mov. Disord. 2020; 35: 994-1001

 

The most important achievements in stroke in 2021 (elaborated by dr hab. n.med Adam Kobayashi, prof. UKSW; This email address is being protected from spambots. You need JavaScript enabled to view it. ; prof. dr hab. n. med. Anna Członkowska: This email address is being protected from spambots. You need JavaScript enabled to view it.)

Global and own:Global and own: As COVID-19 have impact not only on organization problems in stroke units, it also have impact on risk of stroke as well as their severity and outcome. In 2021 several international, multicenter papers were published documenting ten impact of COVID-19 on stroke treatment. In few of them, Polish centers were invovled. Pandemic disease decrease the numbers of intravenous thrombolysis and thrombectomy procedures. In Poland profesor Anna Członkowska was the coordinator of these studies, and over a dozen centers were invovled in data colection. In global perspectvie, there was decrease numbers of neuroradiological procedures (except the ruptured aneurysms), what was caused with limited access to neurosurgical procedures. This work was performer in 2 Polish centers and dr hab. n. med. Adam Kobayahsi coordinated this study. Most other papers in 2021 were according to stroke tretament organization. Use of stroke ambulances may lead to better stroke outcome, due to faster qualification to thombolysis and thrombectomy. The patients with stroke due to large artery occlusion have better prognosis if they are directly admitted to hospital which can perform thrombectomy.
Nogueira RG, Abdalkader M, Qureshi MM. i wsp. Global impact of COVID-19 on stroke care. International journal of stroke: official journal of the International Stroke Society 2021; 16(5): 573-84
Nogueira RG, Qureshi MM, Abdalkader M. i wsp. Global impact of COVID-19 on stroke care and IV thrombolysis. Neurology 2021; 96(23): e2824-e38
Qureshi AI, Agunbiade S, Huang W. i wsp. Changes in neuroendovascular procedural volume during the COVID-19 pandemic: An International Multicenter Study. Journal of neuroimaging : official journal of the American Society of Neuroimaging 2021; 31(1): 171-9
Ebinger M, Siegerink B, Kunz A,.i wsp. Association between dispatch of mobile stroke units and functional outcomes among patients with acute ischemic stroke in Berlin. JAMA 2021; 325(5): 454-66
Grotta JC, Yamal JM, Parker SA. i wsp. Prospective, Multicenter, Controlled Trial of Mobile Stroke Units. NEJM 2021; 385(11): 971-81
Requena M, Olivé-Gadea M, Muchada M. i wsp. Direct to angiography suite without stopping for computed tomography imaging for patients with acute stroke: A Randomized Clinical Trial. JAMA Neurology 2021; 78(9): 1099-107

 

The progres in multiple sclerosis treatment (elaborated by: prof. dr hab.n.med Monika Adamczyk-Sowa; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.)

Global:In 2021 EMA, based on TERIKIDS study, registered teriflunomide in pediatric population patients with MS RR Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.

Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.

Chitnis T, Banwell B, Kappos L, Arnold D, Deiva K, Skripchenko N, Li-Ying Cui, Saubadu S, Hu W, Benamor N, Le-Halpere A, Truffinet P, Tardieu M, Gücüyener K  i wsp.  TERIKIDS Investigators.Lancet Neurol. 2021 Dec;20(12):1001-1011

Ofatumumab, anti-CD-20 monoclonal antibody was registered by EMA for adult MS RR patients.Vumerity (diroximel-fumarate) was approved by European Committe for adult patients with MS RR.

Own: Several papers documenting the impact of Covid-19 infection on course, treatment and vaccination in MS patients..

Adamczyk-Sowa M, Niedziela N, Kubicka-Bączyk K, Wierzbicki K, Jaroszewicz J, Sowa P i wsp. Neurological symptoms as a clinical manifestation of COVID-19: implications for internists. Pol. Arch. Med. Wewn. 2021: 131, 1, 54-62
Nojszewska M, Kalinowska A, Adamczyk-Sowa M. i wsp. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. Pol. J. Neurol. Neurosurg. 2021: 55, 1, 8-11
Nowak-Kiczmer M, Kubicka-Bączyk K, Niedziela N, Adamczyk B, Wierzbicki K, Bartman W, Adamczyk-Sowa M. The course of COVID-19 infection in patients with multiple sclerosis - the experience of one center based on the population of Upper Silesia. Mult. Scler. Relat. Disord. 2021: 52, 1-11
Mado H, Adamczyk-Sowa M. Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations  J. Neurol. 2021: 268, 11, 3998-3999
Mado H, Kubicka-Bączyk K, Adamczyk-Sowa M. Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report. J. Int. Med. Res. 2021: 49, 9, 1-10
Adamczyk-Sowa M,  Mado H, Kubicka-Bączyk K, Jaroszewicz J,Sobala- Szczygieł B, Bartman W, Sowa P i wsp. SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy. Clin. Neurol. Neurosurg. 2021: 201, 1-7

 

Progress in neurosurgery (elaborated by prof. dr hab. n. med. Dariusz Jaskólski: This email address is being protected from spambots. You need JavaScript enabled to view it.) World: Neurosurgery and intelligence

Global: The study with Cognitron’s Great British Intelligence Test aimed to compare cognitive testing scores in neurosurgeons and aerospace engineers to help settle the age old argument of which phrase—“It’s not brain surgery” or “It’s not rocket science”—is most deserved. The neurosurgeons showed significantly higher scores than the aerospace engineers in semantic problem solving. Aerospace engineers showed significantly higher scores in mental manipulation and attention. No difference was found between groups in domain scores for memory, spatial problem solving, problem solving speed, and memory recall speed. When each group’s scores for the six domains were compared with those in the general population, only two differences were significant: the neurosurgeons’ problem solving speed was quicker and their memory recall speed was slower. In conclusion the authors stated, thats’ in situations that do not require rapid problem solving, it might be more correct to use the phrase “It’s not brain surgery.” It is possible that both neurosurgeons and aerospace engineers are unnecessarily placed on a pedestal and that “It’s a walk in the park” or another phrase unrelated to careers might be more appropriate. Other specialties might deserve to be on that pedestal, and future work should aim to determine the most deserving profession.
Usher I, Hellyer P, Lee KS, Leech R, Hampshire A, Alamri A, Chari A. “It’s not rocket science” and “It’s not brain surgery”—“It’s a walk in the park”: prospective comparative study. BMJ 2021;375:e067883 |doi.org/10.1136/bmj-2021-067883

Own: The first coil volume packing density (VPD) decreases the late recanalization rate in ruptured intracranial aneurysms treated with coil embolization (according to statistical results > 10.56%). The objective of this project was to identify a late recanalization predictor in ruptured intracranial aneurysms treated with coil embolization. This goal was achieved by means of a statistical analysis followed by a computational fluid dynamics (CFD) with porous media modelling approach. Porous media CFD simulated the hemodynamics within the aneurysmal dome after coiling. The authors assessed retrospectively morphometric parameters, packing density, first coil volume packing density (1st VPD) and recanalization rate on digital subtraction angiograms (DSA) in 66 aneurysmal subarachnoid hemorrhage patients. In the results the authors proved that’s the model for late recanalization prediction based on 1st VPD is the most important predictor of late recanalization. A cut-off point of 10.56% (sensitivity—0.722; specificity—0.979) was confirmed as optimal in a computational fluid dynamics analysis. The CFD results indicate that pressure at the aneurysm wall and residual flow volume (blood volume with mean fluid velocity > 0.01 m/s) within the aneurysmal dome tended to asymptotically decrease when VPD exceeded 10%. Concluding, the study presented an easy intraoperatively calculable predictor which has the potential to be used in clinical practice as a tip to improve clinical outcomes.
Wiśniewski K, Tomasik B, Tyfa Z, Reorowicz P, Bobeff E. J, Stefańczyk L, Posmyk B.J, Jóźwik K, Jaskólski D.J. Porous media computational fluid dynamics and the role of the first coil in the embolization of ruptured intracranial aneurysms. J. Clin. Med. 2021, 10, 1348.doi.org/10.3390/jcm10071348